Dianthus Therapeutics, Inc. ( DNTH ) Reports Q3 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -12.79% and -39.63%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Day One Biopharmaceuticals, Inc. ( DAWN ) Reports Q3 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of +32.14% and +5.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics, Inc. ( DNTH ) Expected to Beat Earnings Estimates: Should You Buy?
Dianthus Therapeutics, Inc. (DNTH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosing ...
Hansoh and Leads Biolabs clinch US$2.5 billion in global drug licensing deals
Two Chinese drug developers have signed licensing deals that could yield as much as US$2.5 billion in performance-based payments, underscoring growing international confidence in China's life sciences sector. Hansoh Pharmaceutical Group has agreed to license global rights - excluding mainland ...
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
DNTH212 is a bifunctional fusion protein targeting plasmacytoid dendritic cell ( pDC ) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function ...
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized Myasthenia Gravis Positive results from Phase 2 MaGic trial including additional analyses, and ...
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday - Adobe ( NASDAQ:ADBE ) , C3.ai ( NYSE:AI )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. UBS raised C3.ai, Inc. AI price target from $16 to $17. UBS analyst Radi Sultan maintained a Neutral rating.
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
NEW YORK and WALTHAM, Mass., Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases ( "Dianthus" or the "Company" ...
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., Sept. 09, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases ( "Dianthus" or the "Company" ...
Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline - Dianthus Therapeutics ( NASDAQ:DNTH )
Claseprubart at 600mg improved MG-ADL by 5.4 points at Week 13, with early benefits seen from Week 1. No serious side effects or treatment-related discontinuations were reported in the trial. Up Next: Get 5 Dark Horse Stocks Wall Street Is Quietly Loading Up On Dianthus Therapeutics Inc.
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart ( DNTH103 ) in Generalized Myasthenia Gravis - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart ( DNTH103 ) in Generalized Myasthenia Gravis
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference ...
Dianthus Therapeutics, Inc. ( DNTH ) Reports Q2 Loss, Lags Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2.33% and -84.39%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Dianthus ( DNTH ) Q2 Loss Widens 80%
Dianthus Therapeutics ( NASDAQ:DNTH ) , a clinical-stage biotech developing therapies for autoimmune neuromuscular diseases, reported second quarter results on August 7, 2025. Net loss per share ( GAAP ) was $ ( 0.88 ) . GAAP revenue was $0.2 million for Q2 2025.
Earnings Preview: Dianthus Therapeutics, Inc. ( DNTH ) Q2 Earnings Expected to Decline
Dianthus Therapeutics, Inc. (DNTH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seer, Inc. ( SEER ) Reports Q2 Loss, Beats Revenue Estimates
Seer (SEER) delivered earnings and revenue surprises of +15.38% and +8.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 29, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's ...
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - Dianthus Therapeutics ( NASDAQ:DNTH )
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020
Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry ...
Dianthus Therapeutics, Inc. ( DNTH ) Reports Q1 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.65% and 1.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions ( EBS ) Q1 Earnings Top Estimates
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 44.90% and 2.82%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September
MaGic trial exceeded enrollment target of 60 patients ...
Dianthus Therapeutics to Participate in Two Upcoming Investor Events - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., April 29, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. DNTH, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's ...
Dianthus Therapeutics to Participate in Two Upcoming Investor Events
NEW YORK and WALTHAM, Mass., April 29, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the ...
Dianthus Therapeutics, Inc. ( DNTH ) Soars 6.1%: Is Further Upside Left in the Stock?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alnylam ( ALNY ) Surges 11.8%: Is This an Indication of Further Gains?
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Dianthus Therapeutics, Inc. ( DNTH ) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.71% and 5.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors - Dianthus Therapeutics ( NASDAQ:DNTH )
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion
Y-mAbs Therapeutics, Inc. ( YMAB ) Reports Q4 Loss, Lags Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of -15.38% and 0.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. ( CTKB ) Tops Q4 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 16.67% and 9.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health ( GH ) Reports Q4 Loss, Tops Revenue Estimates
Guardant Health (GH) delivered earnings and revenue surprises of -24% and 0.98%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Jazz ( JAZZ ) Surges 5.2%: Is This an Indication of Further Gains?
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc.
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's ...
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. DNTH, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation ...
Powell Industries Reports Weak Sales, Joins Target, QuidelOrtho And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Powell Industries ( NASDAQ:POWL )
U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday. Shares of Powell Industries, Inc. POWL fell sharply in today's pre-market trading after the company reported worse-than-expected fourth-quarter revenue results.
Dianthus Therapeutics, Inc. ( DNTH ) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -25.42% and 102.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences ( GILD ) Q3 Earnings and Revenues Surpass Estimates
Gilead (GILD) delivered earnings and revenue surprises of 27.85% and 7.94%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine ( AANEM ) Annual Meeting - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc.
Strength Seen in Dianthus Therapeutics, Inc. ( DNTH ) : Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Ulta Beauty ( NASDAQ:ULTA )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Friday. Shares of Ulta Beauty, Inc. ULTA fell sharply in today's pre-market trading after the company reported weaker-than-expected results for its second quarter and cut its FY24 guidance.
Dianthus Therapeutics, Inc. ( DNTH ) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -2% and 195.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Dianthus ( DNTH ) Gains 18% in the Past Month: Here's Why
Dianthus (DNTH) shares have rallied 18% in the past month on FDA clearance to initiate a phase II study on its lead candidate, DNTH103, to treat an autoimmune indication. Top-line data is expected in 2026.
Carisma Therapeutics Announces Changes to its Board of Directors
PHILADELPHIA, July 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. ( Nasdaq: CARM ) ( "Carisma" or the "Company" ) , a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of Marella Thorell and David ...
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology ( EAN ) - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., June 28, 2024 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc.
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy ( MMN ) - Dianthus Therapeutics ( NASDAQ:DNTH )
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in 2H 2026 Building a neuromuscular franchise with DNTH103 following the initiation of the Phase 2 MaGic trial in generalized Myasthenia Gravis ( gMG ) in 1Q'24 and planned initiation of a Phase 2 trial in ...
Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy ( MMN )
Top-line results from Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy anticipated in ...
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference - Dianthus Therapeutics ( NASDAQ:DNTH )
NEW YORK and WALTHAM, Mass., May 30, 2024 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. DNTH, a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its participation in the ...
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 ( GLOBE NEWSWIRE ) -- Dianthus Therapeutics, Inc. ( Nasdaq: DNTH ) , a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced its ...
